STOCK TITAN

BD and Wellstar Advance Patient Care and Safety with Medication Management Powered by AI

(Neutral)
(Very Positive)
Tags
AI

BD (NYSE: BDX) announced a strategic partnership with Wellstar Health System on May 5, 2026 to integrate BD Pyxis Pro dispensing and BD Alaris infusion technologies.

Powered by AI in BD Incada, the solution offers enterprise-wide medication inventory visibility, natural-language queries, customizable dashboards, and EMR interoperability with barcode-driven infusion order exchange.

Loading...
Loading translation...

AI-generated analysis. How Rhea-AI works. Not financial advice.

Positive

  • Enterprise-wide medication visibility via AI analytics in BD Incada
  • EMR interoperability enabling barcode-scanned infusion order exchange
  • Custom dashboards to identify trends, reduce waste, and optimize labor
  • Wellstar participation on BD's Strategic Development Council

Negative

  • None.

News Market Reaction – BDX

-1.46%
-1.46% News Effect

On the day this news was published, BDX declined 1.46%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement expands BD’s AI-enabled medication management footprint by integrating BD Pyxis Pr...
Analysis

This announcement expands BD’s AI-enabled medication management footprint by integrating BD Pyxis Pro, BD Alaris and the BD Incada analytics platform across Wellstar’s network. It reinforces a series of AI launches in dispensing, monitoring and research tools, where past AI-tagged news has led to modest average moves of about -0.67%. Investors may watch for additional health system adoptions, usage metrics, and any disclosure tying these solutions to revenue or margin performance in future filings and presentations.

Key Figures

Revenue: $18,544 million Revenue: $16,820 million Net income: $1,100 million +5 more
8 metrics
Revenue $18,544 million Twelve months ended Sep 30, 2025 (continuing operations)
Revenue $16,820 million Twelve months ended Sep 30, 2024 (continuing operations)
Net income $1,100 million Twelve months ended Sep 30, 2025 (continuing operations)
Net income $1,054 million Twelve months ended Sep 30, 2024 (continuing operations)
Diluted EPS $3.81 Twelve months ended Sep 30, 2025 (continuing operations)
Diluted EPS $3.62 Twelve months ended Sep 30, 2024 (continuing operations)
Ownership stake 7.51% Vanguard Capital Management beneficial ownership (21,397,756 shares) as of 03/31/2026
Ownership stake 5.4% Vanguard Portfolio Management beneficial ownership (15,388,359 shares) as of 03/31/2026

Previous AI Reports

4 past events · Latest: Apr 01 (Positive)
Same Type Pattern 4 events
Date Event Sentiment 24h Move Catalyst
Apr 01 AI product launch Positive -0.6% European launch of AI-enabled Pyxis Pro and Incada analytics platform.
Jan 23 AI software release Positive -2.1% Global release of BD Research Cloud 7.0 with AI panel design tool.
Oct 20 AI platform launch Positive +1.0% Launch of BD Incada platform and next-gen Pyxis Pro dispenser.
Apr 21 AI monitoring launch Positive -1.1% Launch of HemoSphere Alta AI-driven hemodynamic monitoring system.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent AI-related launches have often coincided with modest share declines, with three of the last four AI announcements seeing negative next-day moves despite product-focused, innovation-heavy headlines.

Recent Company History

Over the past year, BD has repeatedly highlighted AI-enabled solutions across medication management and monitoring. AI-tagged events include launches of the BD Incada Connected Care Platform, BD Pyxis Pro Dispensing Solution, BD Research Cloud 7.0, and the HemoSphere Alta hemodynamic platform. These initiatives emphasize analytics, automation and connected care. Historically, these AI announcements have produced small average moves of about -0.67% the next day, indicating that product innovation news alone has not consistently driven strong positive price reactions.

Key Terms

artificial intelligence, electronic medical record, emr interoperability, natural-language queries
4 terms
artificial intelligence technical
"Powered by artificial intelligence, the new BD Pyxis™ Pro Dispensing Solution..."
Artificial intelligence is the ability of computers and machines to perform tasks that typically require human thinking, such as understanding language, recognizing patterns, or making decisions. For investors, it matters because AI can enhance efficiency, uncover new insights, and enable smarter strategies, potentially impacting the value and performance of companies that develop or utilize this technology.
electronic medical record medical
"use barcode scanning to send infusion orders directly from the electronic medical record..."
An electronic medical record is a digital version of a patient’s chart that stores clinical notes, test results, prescriptions and treatment history in a secure, searchable system—like a locked, organized digital filing cabinet for a doctor’s office or hospital. Investors care because EMR systems drive recurring software and services revenue, affect healthcare providers’ efficiency and costs, and carry regulatory, cybersecurity and interoperability risks that can influence a company’s profitability and valuation.
emr interoperability technical
"And with BD Alaris™ EMR Interoperability, Wellstar clinicians can use barcode scanning..."
EMR interoperability is the ability of different electronic medical record systems to share, read and use patient health information reliably and securely, like different phones charging from the same outlet or apps speaking the same language. For investors, it matters because better interoperability can lower healthcare costs, speed care delivery, reduce regulatory and legal risk, and create competitive advantages for vendors and providers that can connect systems smoothly and scale services across networks.
natural-language queries technical
"enterprise‑wide visibility into medication inventory, including on‑demand insights through natural‑language queries."
A natural-language query is a question or request written or spoken in everyday speech — what you would type or say to a person — used to ask a database, search engine, or software tool for information. For investors, this matters because it makes complex financial data easier and faster to access and interpret without technical skills, like asking an assistant for a quick summary so you can make timelier, better-informed decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

By integrating the BD Pyxis™ Pro and BD Alaris™ platforms, Wellstar Health System is giving clinicians clearer insight, greater accuracy and simple automation, so they can focus on delivering safer, more consistent care to every patient

FRANKLIN LAKES, N.J. and MARIETTA, Ga., May 5, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a strategic partnership with Wellstar Health System, one of Georgia's largest and most integrated healthcare systems, to enhance the safety and quality of medication delivery for patients across its hospitals and care facilities.

Through this collaboration, Wellstar is building a more connected approach to medication management from the pharmacy to the bedside by combining BD Pyxis™ Pro medication dispensing technologies with BD Alaris™ Infusion Systems. By adopting the latest in dispensing and infusion technology, Wellstar is empowering clinicians with greater accuracy, real‑time visibility, and streamlined workflows, helping them focus more on delivering safe, dependable care to their patients.

Powered by artificial intelligence, the new BD Pyxis™ Pro Dispensing Solution with Analytics in BD Incada™ provides Wellstar with enterprise‑wide visibility into medication inventory, including on‑demand insights through natural‑language queries. Customizable dashboards convert data into actionable intelligence, helping clinicians identify trends to ensure medication availability, reduce medication waste and optimize labor efficiency. And with BD Alaris™ EMR Interoperability, Wellstar clinicians can use barcode scanning to send infusion orders directly from the electronic medical record and receive infusion statuses back into the EMR.

"At Wellstar, our focus is on delivering safe, innovative care to every patient, every time," said Susan Wright, Pharm.D., Vice President, Pharmacy Services at Wellstar Health. "Partnering with BD to implement this technology strengthens our ability to focus on patient-centered programs and empower our teams to deliver care with confidence and compassion."

Wellstar also participates on the Strategic Development Council for BD's Medication Management Solutions business, where Wellstar leaders contribute expertise across enterprise pharmacy operations, medication safety, nursing, and informatics. This input helps inform and shape future innovation at BD and drives next-generation solutions to meet the real‑world challenges faced by large, complex healthcare systems.

"BD is proud to partner with Wellstar to advance medication safety and help ensure patients receive the right medications at the right time," said Connor Bates, Worldwide President for Medication Management Solutions at BD. "By integrating BD Pyxis™ and BD Alaris™ technologies, Wellstar is setting an example of how health systems can achieve connected, intelligent medication management that benefits both patients and clinicians."

This collaboration reflects a shared vision to strengthen safety, efficiency, and patient outcomes across the continuum of care, while positioning Wellstar as a leader in leveraging technology to improve the health of the communities it serves.

About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.

About Wellstar Health System
Wellstar personalizes the patient experience. We call it PeopleCare and it's only possible thanks to our 34,000 team members who provide expert compassionate care for every stage of life. PeopleCare also means we serve our communities as a non-profit health system, providing more than $1 billion annually in charity care and community programs, and operating the largest integrated trauma network in the State of Georgia. We embrace innovation and technology, nurture early-stage companies through our venture firm Catalyst by Wellstar, and train future generations of caregivers with academic institutions including the Medical College of Georgia. Wellstar honors every voice and is one of the Fortune 100 Best Companies to Work For. To learn more, visit Wellstar.org.

Contacts: 




BD Media:

Investors:

Matt Marcus

Shawn Bevec

VP, Public Relations

SVP, Investor Relations

Matt.Marcus@bd.com

Investor_Relations@bd.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-and-wellstar-advance-patient-care-and-safety-with-medication-management-powered-by-ai-302761894.html

SOURCE BD (Becton, Dickinson and Company)

FAQ

What did BD (BDX) announce with Wellstar on May 5, 2026?

BD announced a strategic partnership with Wellstar to integrate BD Pyxis Pro and BD Alaris technologies. According to BD, the collaboration combines dispensing, infusion, AI analytics, and EMR interoperability to improve medication management across Wellstar hospitals and care sites.

How does the BD Pyxis Pro Dispensing Solution with Analytics help Wellstar clinicians?

It provides enterprise-wide visibility into medication inventory and on-demand insights via natural-language queries. According to BD, customizable dashboards convert data into actionable intelligence to help clinicians track availability, reduce waste, and optimize workflows across the system.

What EMR interoperability features are included in the BD and Wellstar collaboration?

The integration supports barcode scanning to send infusion orders from the EMR and return infusion statuses back into the EMR. According to BD, this enables more direct order exchange and status visibility between infusion devices and the electronic medical record.

What role does Wellstar play in BD's product development after the partnership?

Wellstar participates on BD's Strategic Development Council to provide operational expertise across pharmacy, nursing, safety, and informatics. According to BD, that input helps shape future medication-management innovations for large, complex health systems.

What patient-safety benefits does the BD and Wellstar integration aim to deliver?

The collaboration aims to improve accuracy, real-time visibility, and streamlined workflows to support safer medication delivery. According to BD, integrating dispensing, infusion, and analytics is intended to help ensure patients receive the right medications at the right time.